Taori Suchet, Adida Samuel, Kann Michael R, Bhatia Shovan, Sefcik Roberta K, Burton Steven A, Flickinger John C, Zinn Pascal O, Gerszten Peter C
School of Medicine, University of Pittsburgh Medical Center, Pittsburgh , Pennsylvania , USA.
Department of Neurological Surgery, Medical University of South Carolina, Charleston , South Carolina , USA.
Neurosurgery. 2024 Oct 11. doi: 10.1227/neu.0000000000003219.
The role of radiosurgery in the treatment of benign intracranial tumors is well established. However, there are limited long-term follow-up studies on outcomes after stereotactic radiosurgery (SRS) for benign intradural spinal tumors. In this article, we report a large single-institution experience in using SRS to treat patients with benign intradural tumors of the spine.
Overall, 184 patients (55% female) and 207 benign intradural tumors were treated. The median patient age was 52 years (range: 19-93). Tumor histology included schwannoma (38%), meningioma (15%), neurofibroma (21%), hemangioma (9%), hemangioblastoma (8%), hemangiopericytoma (5%), and paraganglioma (4%). Thirty-four (16%) lesions underwent resection before radiosurgery. Twenty-three (11%) lesions were NF1-mutated. The median single-fraction margin dose was 14 Gy (range: 11-20), and the median multifraction margin dose was 21 Gy (range: 15-30).
The median follow-up was 63 months (range: 1-258). At last follow-up, tumors volumetrically regressed (15%), remained stable (77%), or locally progressed (8%, median: 20 months [range: 3-161]) after SRS. The 1-, 5-, and 10-year local control rates were 97%, 92%, and 90%, respectively. On multivariable analysis, the absence of the NF1 mutation ( P = .004, hazard ratio: 0.23, 95% CI: 0.08-0.63) and single-fraction SRS ( P = .007, hazard ratio: 0.24, 95% CI: 0.08-0.68) correlated with improved local control. The median overall survival was 251 months (range: 1-258), and 1-, 5-, and 10-year overall survival rates were 95%, 85%, and 70%, respectively. For patients with pre-existing symptoms, tumor-associated pain and neurological deficits were noted to improve or remain stable in 85% and 87% of cases, respectively. Adverse radiation effects included delayed myelopathy (1%), acute pain flare (9%), dermatitis (0.5%), dysphagia (0.5%), and dysphonia (0.5%).
With long-term follow-up, spine radiosurgery is a safe and effective treatment for benign intradural tumors. In carefully selected patients, even with an NF1 mutation, SRS is associated with a high likelihood of local tumor control.
放射外科在治疗颅内良性肿瘤中的作用已得到充分证实。然而,关于立体定向放射外科(SRS)治疗硬脊膜内良性脊柱肿瘤后的长期随访研究有限。在本文中,我们报告了在一家单一机构使用SRS治疗脊柱硬脊膜内良性肿瘤患者的大量经验。
总共治疗了184例患者(55%为女性)和207个硬脊膜内良性肿瘤。患者中位年龄为52岁(范围:19 - 93岁)。肿瘤组织学类型包括神经鞘瘤(38%)、脑膜瘤(15%)、神经纤维瘤(21%)、血管瘤(9%)、血管母细胞瘤(8%)、血管外皮细胞瘤(5%)和副神经节瘤(4%)。34个(16%)病灶在放射外科治疗前接受了切除术。23个(11%)病灶存在NF1突变。单次分割边缘剂量中位数为14 Gy(范围:11 - 20),多次分割边缘剂量中位数为21 Gy(范围:15 - 30)。
中位随访时间为63个月(范围:1 - 258个月)。在最后一次随访时,放射外科治疗后肿瘤体积缩小(15%)、保持稳定(77%)或局部进展(8%,中位时间:20个月[范围:3 - 161个月])。1年、5年和10年的局部控制率分别为97%、92%和90%。多变量分析显示,不存在NF1突变(P = 0.004,风险比:0.23,95%置信区间:0.08 - 0.63)和单次分割SRS(P = 0.007,风险比:0.24,95%置信区间:0.08 - 0.68)与更好的局部控制相关。中位总生存期为251个月(范围:1 - 258个月),1年、5年和10年的总生存率分别为95%、85%和70%。对于已有症状的患者,肿瘤相关疼痛和神经功能缺损在85%和87%的病例中分别有所改善或保持稳定。放射不良反应包括迟发性脊髓病(1%)、急性疼痛发作(9%)、皮炎(0.5%)、吞咽困难(0.5%)和发音困难(0.5%)。
经过长期随访,脊柱放射外科是治疗硬脊膜内良性肿瘤的一种安全有效的方法。在精心挑选的患者中,即使存在NF1突变,SRS也有很高的局部肿瘤控制可能性。